Patologia orale e del massiccio facciale. Lesioni e condizioni potenzialmente maligne della mucosa orale: attualità e prospettive diagnostiche e terapeutiche
E. Cortesi - Department of Experimental Medicine
University La Sapienza, Rome, Italy
S.Iacobelli
- Department of Oncology and Neurosciences
University G. D’Annunzio, Chieti, Italy
Course description
Colorectal cancer remains one of the most challenging problema worldwide. The Course: “Highlights in the management of colorectal cancer” is dedicated to an in- depth discussion of the best care options for the comprehensive management of patients with early-stage or advanced colorectal cancer. A significant emphasis will be given to current controversies on the application of emerging clinical trial findings to daily practice. The optimal integration of biologic agents, such as EGFR inhibitors, antiangiogenesis agents, or other novel agents, into current chemotherapy regimens will be addressed. There will be updates on clinical data from the major national and international cooperative groups. Multidisciplinary approaches to the treatment of colorectal cancer will be discussed, including surgery and/or ablation in patients with liver metastases. Practical strategies to minimize neuropathy and skin toxicities will be offered, as well as strategies in choosing the best care options for elderly patients.
The educational program is directed primarily toward medical oncologists, surgical oncologists, gastroenterologists, and fellows interested in colorectal cancer. At the conclusion of the Course, participants should be able to: (i) choose optimal therapy for patients with newly diagnosed metastatic disease; (ii) evaluate the efficacy of oral and infusional fluoropyrimidines; (iii) select optimal adjuvant therapy for early-stage disease; (iv) manage the integration of antiangiogenic agents into current chemotherapeutic treatment regimens; (v) determine the optimal use of EGFR inhibitors in combination with chemotherapy in daily practice; (vi) assess the best care options for elderly patients; (vii) compare standard infusional with chronomodulated chemotherapy as treatment for advanced disease.
We do hope that participants will remember this Course of the Mediterranean School of Oncology as a highlight of up-to-date training in the field of colorectal cancer.
THURSDAY, February 1
10.00 - 10.45 Welcome addresses and presentation of the course (S. Iacobelli, Chieti -
E. Cortesi, Rome) go to slides 10.45 - 13.00
CRC screening: Questions and answers (M. Crespi, Rome) go to slides
Recent advances in CRC surgery (A. Montori, Rome)go to slides
Predictive markers of response to drugs (G. Biasco, Bologna) go to slides 13.00 - 14.00LUNCH
14.00 - 14.45
Advances in the adjuvant treatment of colorectal cancer (S. Cascinu, Ancona) go to slides 14.45 - 16.15 Round Table on “Therapeutic Antibodies”
Cetuximab (P. Marchetti, Rome) go to slides
Bevacizumab (V. Adamo, Messina)go to slides
Panitumumab (E. Cortesi, Rome) go to slides 16.15 - 17.00
Novel targeted therapies (G. Tortora, Naples) go to slides
